premenstrual%20dysphoric%20disorder
PREMENSTRUAL DYSPHORIC DISORDER
Premenstrual dysphoric disorder is a cyclical disorder presenting with distressing mood and behavioral symptoms that occur during the late luteal phase of the ovulatory cycle; it is a severe form of premenstrual syndrome.
It results in considerable impairment of the patient's personal functioning that occurs in approximately 5% of women of reproductive age.

Premenstrual%20dysphoric%20disorder Diagnosis

Diagnosis

Diagnostic Criteria for Premenstrual Dysphoric Disorder (PMDD)
  • Presence of ≥1 of the 1st four symptoms and ≥5 of any symptom occurring during the last week of the luteal phase with remission starting within a few days after the onset of menses and absent in the week postmenses
    1. Appreciable depressed mood, feeling of hopelessness or self-depreciation
    2. Marked tension, anxiety or feelings “on edge” or “keyed up”
    3. Appreciable affective lability such as sudden sadness or tearfulness or having increased sensitivity to rejection
    4. Continual and marked anger or irritability or increased interpersonal conflicts
    5. Decreased interest in usual activities
    6. Subjective feeling of difficulty in concentrating
    7. Lethargy, marked lack of energy, easy fatigability
    8. Hypersomnia or insomnia
    9. Subjective feeling of being overwhelmed or out of control
    10. Change in appetite, overeating or cravings for certain foods
    11. Physical symptoms (eg breast swelling/tenderness, sensation of bloating/weight gain, joint or muscle pain, headache)
  • Appreciable interference with school/work or with usual social activities or relationships with others
  • The disturbance is not a mere exacerbation of the symptoms of another disorder (eg major depression, panic disorder)
  • Confirmation of the 3 criteria above by prospective daily ratings during at least 2 consecutive symptomatic menstrual cycles
    • Diagnosis may be provisional prior to confirmation by daily ratings
  • The symptoms are not due to the effects of a medication or another medical condition, other treatment, or drug of abuse

Diagnosis and Treatment Strategies

  • Take a thorough medical history
    • Personal and social history may reveal trauma or sexual abuse
  • Patient should record symptoms for 2 menstrual cycles during which lifestyle-related interventions are begun
    • May use standardized daily symptom calendars such as the Calendar of Premenstrual Experiences (COPE) or the Daily Record of Severity of Problems 
      • COPE, developed by the University of California, San Diego (UCSD), is a daily scoring sheet that assigns a severity score to the common physical (eg bloating, swelling, headache, breast tenderness) and behavioral symptoms (eg depression, irritability, confusion, angry outbursts) during the menstrual cycle 
      • A score of <40 during days 3-9 of the menstrual cycle added with score of >42 during the last 7 days of the cycle has been demonstrated to be a predictor of women meeting inclusion criteria for PMDD
    • If patient remains symptomatic after 2 months of charting and lifestyle modifications, then pharmacotherapy should be considered
    • If patient with PMS fails pharmacotherapy and has severe symptoms, management by a multidisciplinary team utilizing a holistic approach (eg gynecologist, mental health practitioner, dietician) may be warranted 
  • A one-time screening process using a checklist of common symptoms may be more feasible in clinical practice
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Audrey Abella, 6 days ago
A pilot telemedicine initiative may be an alternative for facilitating delivery of intravenous iron (IVI) for individuals requiring iron supplementation.